Shares of UCB SA (OTCMKTS:UCBJF – Get Free Report) passed below its fifty day moving average during trading on Wednesday . The stock has a fifty day moving average of $193.56 and traded as low as $190.50. UCB shares last traded at $192.00, with a volume of 2 shares changing hands.
UCB Trading Up 0.5 %
The firm’s 50-day moving average price is $193.56 and its 200 day moving average price is $183.65. The company has a debt-to-equity ratio of 0.33, a current ratio of 1.19 and a quick ratio of 0.78.
About UCB
UCB SA, a biopharmaceutical company, develops products and solutions for people with neurology and immunology diseases worldwide. The company's primary products include Cimzia for inflammatory TNF mediated diseases, as well as ankylosing spondylitis, axial spondyloarthritis, Crohn's disease, non-radiographic axial spondyloarthritis, plaque psoriasis, psoriatic arthritis, and rheumatoid arthritis; Vimpat, Keppra, and Briviact for epilepsy; Neupro for Parkinson's disease and restless legs syndrome; Nayzilam, a nasal spray rescue treatment for epilepsy seizure clusters; and Zyrtec and Xyzal for allergies.
Recommended Stories
- Five stocks we like better than UCB
- EV Stocks and How to Profit from Them
- Will Alibaba’s $53B AI Bet Be the Key to Tech Supremacy?
- How to Effectively Use the MarketBeat Ratings Screener
- Builders FirstSource Is Laying the Foundation for a Rebound
- 3 Stocks to Consider Buying in October
- Domino’s Pizza Delivers a Buying Opportunity
Receive News & Ratings for UCB Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for UCB and related companies with MarketBeat.com's FREE daily email newsletter.
